☆ 4.4 Review

Efficacy and safety of Y-90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma

SEMINARS IN ONCOLOGY (2003)

Get Full Text
Add to Collection

Journal

SEMINARS IN ONCOLOGY
Volume 30, Issue 6, Pages 11-16

Publisher

W B SAUNDERS CO
DOI: 10.1053/j.seminoncol.2003.10.007

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.